CLOT Conversations

Thrombosis Canada

Unlock the latest breakthroughs in thrombosis diagnosis and management with CLOT Conversations - the must-listen podcast for healthcare professionals. Join hosts Dr Jameel Abdulrehman, a Hematologist with specialization in Thrombosis and Hemostasis at the University Health Network in Toronto, and David Airdrie, the Executive Director of Thrombosis Canada, as they delve into new research and explore the evolving field of thrombosis in 15 to 30 minute easily digestible episodes. Learn from the experts and stay ahead of the curve with Thrombosis Canada, the organization dedicated to promoting excellent patient care and improved outcomes for patients with thrombosis. Access our vast resources, tools, and programs at https://thrombosiscanada.ca and stay informed with CLOT Conversations - your go-to source for all things thrombosis.

  1. 16/12/2025

    WAVe Study: Cancer, Obesity, Anticoagulation with Dr Tzu-Fei Wang and Dr Gregoire Le Gal

    Send us a text Obesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps. In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluating weight-adjusted dalteparin dosing in patients over 90 kg with acute cancer-associated venous thromboembolism. The conversation examines bleeding and thrombotic outcomes, mortality, and trough anti-Xa levels, including insights into bioaccumulation and twice-daily versus once-daily dosing. The guests also address study limitations, dose capping in patients with very high body weight, and how WAVe fits into current practice amid increasing DOAC use. This episode provides practical, evidence-informed guidance for clinicians navigating anticoagulation decisions in obese patients with cancer. To access the full publication:  https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.70127  Please consider supporting Thrombosis Canada by donating today or consider a monthly donation starting at $10: ThrombosisCanada.ca/donate Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    22 min
  2. 03/12/2025

    ROXI-VTE Trials Explained: Dr. Jeff Weitz on Next-Generation Thrombosis Prevention

    Send us a text In this episode of CLOT Conversations, co-hosts Dr. Jamil Abdul-Rahman and Dr. Maha Othman have an in-depth discussion with leading thrombosis expert Dr. Jeff Weitz. Together, they unpack new findings from The Lancet on RGN-9933 and RGN-7508, two investigational factor XI inhibitors evaluated in the ROXI-VTE I and II phase-2 trials. These studies examine how targeted inhibition of factor XI may reduce post-operative venous thromboembolism with potentially lower bleeding risk than current anticoagulants. Dr. Weitz explains the distinct mechanisms of the two antibodies, the role of factor XII-mediated activation in post-operative VTE, key efficacy and safety outcomes, and how these early-phase studies set the stage for ongoing phase-2 and phase-3 trials—including ROXI-CATH, ROXI-Aspirin, and emerging AF and stroke-prevention research. This episode is essential listening for clinicians interested in the rapidly evolving landscape of anticoagulation and next-generation therapies that may offer safer options for patients undergoing orthopedic surgery and beyond. Read the full Lancet publication by clicking on the link below and explore more thrombosis resources at thrombosiscanada.ca. Become a Thrombosis Champion, be a monthly donor at https://thrombosiscanada.ca/donate https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02097-5/abstract [Note: full access requires a subscription] Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    22 min
  3. 24/07/2025

    Mapping Cancer's Hidden Risk—A Global Look at Blood Clots

    Send us a text Did you know that nearly 1 in 10 cancer patients worldwide may develop a potentially deadly blood clot? In this episode, we speak with researcher Jordan Harry, lead author of a landmark systematic review just published in Cancer Epidemiology, that uncovers which solid tumors carry the highest risk of venous thromboembolism (VTE) and where in the world patients are most vulnerable. Jordan walks us through surprising insights from their analysis of over 120 studies:  🔹 Why gastroesophageal, ovarian, and brain cancers top the list for clot risk  🔹 What the data reveals about sex-based differences  🔹 How global gaps in reporting may be leaving patients behind  🔹 And what a cancer survivor told her that changed how she views her work This isn’t just another research summary, it’s a conversation about saving lives by recognizing the often-overlooked danger of cancer-associated thrombosis. If you care about improving outcomes in oncology or want to understand the real-world impact of VTE in cancer care, this is a must-listen. To access the ISTH Common Data Elements mentioned in this episode: https://isth.breakthrough.healthcare/ To access the Thrombosis Canada Cancer-Associated Thrombosis resources for patients: https://thrombosiscanada.ca/cancer To access the publication: https://www.sciencedirect.com/science/article/abs/pii/S1877782125000232 Ref: Jordan Harry, Regan Bucciol, Deirdre Finnigan, Hussein Hashem, Ahmad Araki, Maha Othman, The incidence of venous thromboembolism by type of solid cancer worldwide: A systematic review, Cancer Epidemiology, Volume 95, 2025, 102764, ISSN 1877-7821, https://doi.org/10.1016/j.canep.2025.102764. Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    23 min

About

Unlock the latest breakthroughs in thrombosis diagnosis and management with CLOT Conversations - the must-listen podcast for healthcare professionals. Join hosts Dr Jameel Abdulrehman, a Hematologist with specialization in Thrombosis and Hemostasis at the University Health Network in Toronto, and David Airdrie, the Executive Director of Thrombosis Canada, as they delve into new research and explore the evolving field of thrombosis in 15 to 30 minute easily digestible episodes. Learn from the experts and stay ahead of the curve with Thrombosis Canada, the organization dedicated to promoting excellent patient care and improved outcomes for patients with thrombosis. Access our vast resources, tools, and programs at https://thrombosiscanada.ca and stay informed with CLOT Conversations - your go-to source for all things thrombosis.

You Might Also Like